Home » Stocks » QURE

uniQure N.V. (QURE)

Stock Price: $32.86 USD 2.38 (7.81%)
Updated May 6, 2021 4:00 PM EDT - Market closed
After-hours: $30.48 -2.38 (-7.24%) May 6, 4:48 PM
Market Cap 1.51B
Revenue (ttm) 37.51M
Net Income (ttm) -125.02M
Shares Out 45.92M
EPS (ttm) -2.81
PE Ratio n/a
Forward PE 27.93
Dividend n/a
Dividend Yield n/a
Trading Day May 6
Last Price $32.86
Previous Close $30.48
Change ($) 2.38
Change (%) 7.81%
Day's Open 33.78
Day's Range 31.85 - 33.78
Day's Volume 692,835
52-Week Range 28.58 - 71.45

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Moderna, Inc. (NASDAQ: MRNA). uniQure N.V.

Other stocks mentioned: MRNA, NVAX
8 hours ago - Benzinga

KING OF PRUSSIA, Pa., May 6, 2021 /PRNewswire/ -- Global biotherapeutics leader CSL Behring today announced the closing of its global Commercialization and License agreement with uniQure (NASDAQ: QURE) ...

11 hours ago - PRNewsWire

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, May 03, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe ...

3 days ago - GlobeNewsWire

UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 28, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with sever...

1 week ago - GlobeNewsWire

uniQure (QURE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

1 week ago - Zacks Investment Research

Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR Therapeutics AG (NASDAQCR...

Other stocks mentioned: AXSM, VYGR, CRSP, RVPH
1 week ago - Benzinga

The Food and Drug Administration said Monday that Uniqure can resume testing its hemophilia B gene therapy, and QURE stock popped. The hold followed a patient's liver cancer diagnosis.

1 week ago - Investors Business Daily

The FDA has removed the clinical hold on uniQure NV's (NASDAQ: QURE) hemophilia B gene therapy program after determining the company had satisfactorily addressed all identified issues related to a singl...

1 week ago - Benzinga

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, April 26, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with sever...

1 week ago - GlobeNewsWire

Publication in Science Translational Medicine shows local striatal delivery of microRNA-gene therapy results in widespread brain huntingtin protein lowering in Huntington's disease minipigs Publication ...

4 weeks ago - GlobeNewsWire

~ Enrollment of second dose cohort expected to begin in 3Q 2021 ~

1 month ago - GlobeNewsWire

LEXINGTON, Mass. and AMSTERDAM, April 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...

1 month ago - GlobeNewsWire

We believe that uniQure stock (NASDAQ: QURE), a gene therapy company, is a good buying opportunity at the present time. QURE stock trades near $30 currently and it is, in fact, down 53% from its pre-Cov...

1 month ago - Forbes

Biotech company Uniqure said Monday an investigation shows its hemophilia B gene therapy likely wasn't the culprit in a patient's cancer diagnosis. QURE stock popped on the news report.

1 month ago - Investors Business Daily

Humanigen, Inc. (NASDAQ: HGEN), uniQure N.V. (NASDAQ: QURE), bluebird bio, Inc. (NASDAQ: BLUE) and Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) were among the biotech gainers on Monday.

Other stocks mentioned: BLUE, HGEN, AMPH
1 month ago - Benzinga

Uniqure NV (NASDAQ: QURE) has reported results of a comprehensive investigation into the case of hepatocellular carcinoma (HCC) diagnosed in one patient in the HOPE-B pivotal trial of etranacogene dezap...

1 month ago - Benzinga

~ Independent investigation shows that etranacogene dezaparvovec is highly unlikely to be the cause of HCC in HOPE-B pivotal trial ~

1 month ago - GlobeNewsWire

With all due respect to Elton John, the real Rocket Man is in Cranbury, New Jersey.

Other stocks mentioned: AVRO, BLUE, BOLD, ORTX, RCKT, SRPT
1 month ago - GuruFocus

uniQure (QURE) delivered earnings and revenue surprises of 98.72% and -59.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

~ Six patient procedures now completed in Phase I/II for Huntington's disease, including two procedures conducted in February 2021, with full enrollment of first cohort expected mid-2021 ~

2 months ago - GlobeNewsWire

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Feb. 26, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe...

2 months ago - GlobeNewsWire

UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 months ago - Zacks Investment Research

LEXINGTON, Mass. and AMSTERDAM, The Netherlands, Feb. 01, 2021 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe...

3 months ago - GlobeNewsWire

NEW YORK, Dec. 23, 2020 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of uniQure N.V. ("uniQure" or the "Company") (NASDAQ: QURE). Such investors are advised to contact Ro...

4 months ago - PRNewsWire

Crispr Therapeutics, Editas Medicine and Intellia Therapeutics were ablaze Monday as all three genetics stocks touched highs. Uniqure stock fell on a clinical hold for its gene therapy test.

Other stocks mentioned: EDIT, NTLA
4 months ago - Investors Business Daily

A clinical hold is weighing on the biotech's shares today.

4 months ago - The Motley Fool

After an incredibly wild and wooly year for investors, many across Wall Street are cautiously optimistic for 2021.

Other stocks mentioned: ACAD, NBIX, VRTX, ZGNX
4 months ago - 24/7 Wall Street

Uniqure NV (NASDAQ: QURE) shares are moving sharply to the downside after the gene therapy company announced a setback to its clinical study. What Happened: Lexington, Massachusetts-based uniQure said t...

4 months ago - Benzinga

Company to hold conference call today at 8:30 a.m. ET Company to hold conference call today at 8:30 a.m. ET

4 months ago - GlobeNewsWire

We discuss a few attractive biotech companies that flaunt solid product portfolios, deep pipelines and lucrative valuations to emerge as likely acquisition targets in 2021.

Other stocks mentioned: BMRN, DCPH, RGNX
4 months ago - Zacks Investment Research

~ Sustained FIX Activity at Therapeutic Levels1 with a Mean of 44% of Normal at Two Years After Administration of Etranacogene Dezaparvovec in Phase IIb Study ~

4 months ago - GlobeNewsWire

The health care sector as a whole has been a top performer this year, and there is every reason to believe that strong performance will carry through to 2021.

Other stocks mentioned: ACAD, CVS, HR
5 months ago - 24/7 Wall Street

LEXINGTON, Mass and AMSTERDAM, Dec. 02, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, to...

5 months ago - GlobeNewsWire

~ Strong P resence at ASH Featuring Five P resentations , Including Late-Breaking Oral Presentation on HOPE-B Pivotal Trial ~

5 months ago - GlobeNewsWire

UniQure NV (NASDAQ: QURE) shares were advancing to four-month highs Thursday in reaction to a positive clinical data readout. What Happened: The Lexington, Massachusetts-based company announced positive...

5 months ago - Benzinga

Shares of QURE stock bounded higher Thursday after Uniqure reported promising results for its hemophilia B gene therapy. The company says the drug improved clotting protein at 26 weeks.

5 months ago - Investors Business Daily

~ Phase III study in 54 patients met primary endpoint with mean Factor IX activity of 37% of normal at 26 weeks ~

5 months ago - GlobeNewsWire

LEXINGTON, Mass. and AMSTERDAM, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, t...

6 months ago - GlobeNewsWire

LEXINGTON, Mass. and AMSTERDAM, the Netherlands, Nov. 04, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe...

6 months ago - GlobeNewsWire

uniQure (QURE) delivered earnings and revenue surprises of -171.18% and -98.82%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

~ Enrolled First Four Patients in Phase I/II Clinical Trial of AMT-130 in Huntington's Disease ~

6 months ago - GlobeNewsWire

Marc Schneidman's Aquilo Capital Management is a San Francisco-based, healthcare-focused long/short hedge fund that was founded in 2010. The fund uses CIO Schneidman's 20 years of industry expertise in ...

Other stocks mentioned: BPMC, ANAB, DRNA, SPRO
6 months ago - Insider Monkey

While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious...

6 months ago - Insider Monkey

UniQure (QURE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

LEXINGTON, Mass. and AMSTERDAM, Oct. 13, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, t...

6 months ago - GlobeNewsWire

Gene therapy - which aims to treat diseases by essentially inserting a gene into a patient’s cells rather than via drugs or surgery - was a hot trend in the biotech space, but investor interest in the s...

Other stocks mentioned: RGNX, SRPT, VYGR
7 months ago - Forbes

LEXINGTON, Mass. and AMSTERDAM, Sept. 30, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, ...

7 months ago - GlobeNewsWire

~ Independent Data Safety Monitoring Board Recommends Proceeding with Study Enrollment; No Significant Safety Concerns Observed to Prevent Further Dosing ~ ~ Independent Data Safety Monitoring Board Rec...

7 months ago - GlobeNewsWire

About QURE

uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; ... [Read more...]

Industry
Biotechnology
IPO Date
Jun 20, 2007
Stock Exchange
NASDAQ
Ticker Symbol
QURE
Full Company Profile

Financial Performance

In 2020, uniQure's revenue was $37.51 million, an increase of 415.23% compared to the previous year's $7.28 million. Losses were -$125.02 million, 0.66% more than in 2019.

Financial Statements

Analyst Forecasts

According to 19 analysts, the average rating for uniQure stock is "Strong Buy." The 12-month stock price forecast is 65.81, which is an increase of 100.27% from the latest price.

Price Target
$65.81
(100.27% upside)
Analyst Consensus: Strong Buy